CJC Open最新文献_第7页

The Association Between Duration of Menopausal Hormone Therapy and Cardiovascular Health 绝经期激素治疗持续时间与心血管健康的关系

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.04.041

N. Gulamhusein, S. Dumanski, T. Harrison, S. Butalia, S. Ramesh, D. Sola, S. Ahmed

引用次数: 0

Estimation of the Prevalence of Cardiometabolic Screening Among Women With Polycystic Ovary Syndrome in Alberta 阿尔伯塔省多囊卵巢综合征妇女心脏代谢筛查患病率的估计

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.04.068

J. Ha, J. Yamamoto, R. Vettese, J. Benham

引用次数: 0

Impact of Pregnancy on Atrial Connexins 40 and 43 in Mice 妊娠对小鼠心房连接蛋白40和43的影响

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.04.024

É. Leblanc, V. Long, F. Dierick, C. Fiset

引用次数: 0

Sex Differences in the Cognitive Recovery of Adults With Cardiac Arrest and Myocardial Infarction 成人心脏骤停和心肌梗死患者认知恢复的性别差异

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.04.031

S. Kelly, D. Debicki, L. Norton, A. Owen

引用次数: 0

Iatrogenic Traumatic Regional Pericarditis Secondary to Chest Tube Placement: A Case Report 置胸管继发医源性外伤性区域性心包炎1例

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.04.001

David Y. Ji MD , Connor J. Prosty MD , Kelly Garbis MD , Nadia Giannetti MD

引用次数: 0

Implementation of Pharmacist Case-Finding and Care Pathway Intervention for Vascular Prevention (PRxOACT): Protocol for a Randomized Controlled Trial 实施药剂师病例发现和护理途径干预血管预防（PRxOACT）：一项随机对照试验方案

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.03.011

Shania Liu BPharm (Hons), PhD , Ross T. Tsuyuki BSc(Pharm), PharmD, MSc , Michelle M. Graham MD , Dorothy Nelson (patient partner) , Gary Semeniuk (patient partner) , Yazid N. Al Hamarneh BSc (Pharm), PhD

{"title":"Implementation of Pharmacist Case-Finding and Care Pathway Intervention for Vascular Prevention (PRxOACT): Protocol for a Randomized Controlled Trial","authors":"Shania Liu BPharm (Hons), PhD , Ross T. Tsuyuki BSc(Pharm), PharmD, MSc , Michelle M. Graham MD , Dorothy Nelson (patient partner) , Gary Semeniuk (patient partner) , Yazid N. Al Hamarneh BSc (Pharm), PhD","doi":"10.1016/j.cjco.2025.03.011","DOIUrl":"10.1016/j.cjco.2025.03.011","url":null,"abstract":"<div><div>Cardiovascular (CV) disease (CVD) is the leading cause of death worldwide. The risk factors contributing to CVD development have been well known for decades, but treatment gaps persist. Pharmacists are frontline primary healthcare providers whose interventions to lower CV risk are supported by rigorous evidence. However, efforts to support the widespread implementation of pharmacist interventions to reduce CV risk are needed. To support such implementation, we developed an electronic tool (the “Care Pathway”) for guideline-directed assessment, prescription, and follow-up for CVD risk reduction that incorporates shared decision-making. The aim of this trial is to determine the impact of the pharmacist-led Care Pathway intervention on participants’ estimated risk for major CV events. This investigator-initiated, multicentre, open-label, randomized controlled trial will include 982 patients (aged ≥ 18 years) with ≥ 1 risk factor for CVD. Patients will be randomized in a 1:1 ratio to receive either a pharmacist-led Care Pathway intervention or usual care. Participants’ estimated CV risk will be calculated at baseline and at a 6-month follow-up evaluation. The primary outcome is the difference in change in estimated CV risk from baseline to the 6-month follow-up evaluation between the groups. Pharmacist-led assessment and management of patients’ CV risk factors may serve as an effective intervention to reduce patients’ estimated risk for major CV events. Formal evaluation of widespread implementation of a Care Pathway intervention will be conducted for the first time in a pharmacy practice CV risk–reduction trial.</div></div><div><h3>Clinical Trial Registration</h3><div>The University of Alberta Human Research Ethics Board (Pro00139142). NCT06405880.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 6","pages":"Pages 821-831"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex-Specific Inclusion of Patients with Cardiovascular Disease in Exercise Research in Canada 加拿大运动研究中心血管疾病患者的性别特异性纳入

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.03.022

Isabela R. Marçal MSc, Carley D. O’Neill PhD, Matheus Hausen PhD, Marina Mitra MSc, Sarah Visintini MLIS, Jennifer L. Reed R. Kin, PhD

引用次数: 0

Sex-Based Differences in Epicardial Adipose Tissue Volume and Association With Histological Acute Cellular Rejection Among Post Cardiac Transplant Patients 心脏移植后患者心外膜脂肪组织体积的性别差异及其与组织学急性细胞排斥反应的关系

IF 2.5

CJC Open Pub Date : 2025-06-01 DOI: 10.1016/j.cjco.2025.04.044

B. Mengesha, M.C. Caires, R. DeKemp, R. Beanlands, B. Chow, D. Dey, S. Chih, K.M. Boczar

引用次数: 0

Monitoring, Managing and Preventing Cardiovascular Risks in Women With Hypertensive Disorders During Pregnancy: A Scoping Review 妊娠期高血压疾病妇女心血管风险的监测、管理和预防：一项范围综述